| Literature DB >> 29755455 |
Johanna Meier-Soelch1, Liane Jurida1, Axel Weber1, Doris Newel1, Johnny Kim2, Thomas Braun2, M Lienhard Schmitz3, Michael Kracht1.
Abstract
The potent proinflammatory cytokine interleukin (IL)-1 triggers gene expression through the NF-κB signaling pathway. Here, we investigated the cofactor requirements of strongly regulated IL-1 target genes whose expression is impaired in p65 NF-κB-deficient murine embryonic fibroblasts. By two independent small-hairpin (sh)RNA screens, we examined 170 genes annotated to encode nuclear cofactors for their role in Cxcl2 mRNA expression and identified 22 factors that modulated basal or IL-1-inducible Cxcl2 levels. The functions of 16 of these factors were validated for Cxcl2 and further analyzed for their role in regulation of 10 additional IL-1 target genes by RT-qPCR. These data reveal that each inducible gene has its own (quantitative) requirement of cofactors to maintain basal levels and to respond to IL-1. Twelve factors (Epc1, H2afz, Kdm2b, Kdm6a, Mbd3, Mta2, Phf21a, Ruvbl1, Sin3b, Suv420h1, Taf1, and Ube3a) have not been previously implicated in inflammatory cytokine functions. Bioinformatics analysis indicates that they are components of complex nuclear protein networks that regulate chromatin functions and gene transcription. Collectively, these data suggest that downstream from the essential NF-κB signal each cytokine-inducible target gene has further subtle requirements for individual sets of nuclear cofactors that shape its transcriptional activation profile.Entities:
Keywords: IL-1; NF-κB; chromatin; coactivator; corepressor; shRNA screen; transcription
Mesh:
Substances:
Year: 2018 PMID: 29755455 PMCID: PMC5934416 DOI: 10.3389/fimmu.2018.00775
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Design and execution of the small-hairpin (sh)RNA screens for murine nuclear cofactors of IL-1 signaling. For screen I, 4–5 shRNAs directed at up to four different nuclear targets per 48-well plate were transfected in duplicates as shown. In screen II, 4–5 shRNAs per nuclear target were pooled and transfected into a single well resulting in screening of 20 nuclear targets per plate (not shown). In both screens, empty vector (pLKO.1) with no insert or an insert encoding a scrambled shRNA sequence (pLKO.1-scr.) were used as controls on each of the plates. Cells transfected with pLKO.1 encoding a GFP cDNA were used to monitor transfection efficiency on each individual plate by fluorescence microscopy (left image) and by phase contrast plus fluorescence microscopy (right image) as shown by the insets. The scale bar is 100 µm. For each screen, 3.5 × 104 cells were seeded per well. One day later, 270 ng of DNA were transfected using Lipofectamine LTX plus reagent®. Cells were selected for 48 h in 1 µg/ml puromycin. Then, half of the cells on each plate were left untreated. The other half was stimulated for 3 h (screen I) or 1 h (screen II) with IL-1α (10 ng/ml). Thereafter, cells were lysed, and RT reactions and preamplifications of cDNAs were performed using the PreAmp Cells-to-CtTM Kit and gene specific primers for the IL-1-inducible target gene Cxcl2 and the two “housekeeping” genes ActB (screen I only) and Ube2l3. Finally, preamplified PCR products were subjected to quantitative (q)PCR using Taqman assays and mRNA expressions levels were quantified based on their cycle threshold (ct) value using an ABI7500 instrument. Ct values were used for all further calculations.
Figure 2Distribution of mRNA measurements and changes of mRNA expression levels by shRNA-mediated knockdown of 170 nuclear cofactors using 4–5 transfected shRNAs per target. (A) For screen I, murine embryonic fibroblast (Mef) cells were transfected with 791 shRNA vectors representing 170 nuclear cofactors on a total of 43 plates according to the scheme shown in Figure 1. On each plate, empty pLKO.1, pLKO.1 encoding a scrambled shRNA, and pLKO.1 encoding GFP were transfected as controls. After 48 h of selection in puromycin, half of the cells per plate were left untreated (-, gray boxes) or were stimulated with IL-1 (blue boxes) for 3 h and mRNA measurements for ActB, Ube2l3, and Cxcl2 were performed as described in the legend of Figure 1. Box plots show the distribution of all cycle threshold (ct) values obtained. (B) A repeat experiment (screen II) was performed under identical conditions with the two following modifications: (i) the shRNA encoding vectors for each of the 170 nuclear targets were combined and the pool was transfected into a single well on a total of 9 plates and (ii) cells were stimulated with IL-1 for 1 h. Box plots show the distribution of all ct values obtained. (C) For all target genes analyzed in screen I, individual ct values obtained for Cxcl2 were normalized to the ct values of Ube2l3. The resulting Δct values of the 4–5 shRNAs per target were averaged and used to calculate differences in mRNA expression levels between untreated or IL-1-stimulated cells and relative to the vector (pLKO.1)-transfected control cells as shown by the equations. The graph shows the ranked Z-scores of the resulting ΔΔct values. (D) An identical analysis was performed and visualized by ranked Z-scores of ΔΔct values obtained from screen II. (E) Combined summary from both screens showing the nuclear cofactors that affect Cxcl2 mRNA expression in untreated cells (basal level) or in IL-1-treated cells (IL-1 levels) or the extent of IL-1-mediated regulation (IL-1 regulation) as compared to the vector control cells. The selection is based on shRNA transfections resulting in a Z-score > or < 1 SD in both screens. Colors indicate the direction of the shRNA effect (blue suppression, red induction of mRNA levels) thereby defining the role of the downregulated nuclear factor as coactivator or corepressor.
Figure 3Validation of screen results further defines coactivators and corepressors of Cxcl2. (A) Murine embryonic fibroblast (Mef) cells were transfected with empty pLKO.1 or with pooled shRNAs directed against Sin3a or Mbd3. After 48 h of selection in puromycin, cells were treated with IL-1 for 1 h or were left untreated. Then, total RNA was isolated and mRNA expression of Cxcl2, Sin3a, Mbd3 and Ube2l3 was determined by conventional RT-qPCR. Expression values of Cxcl2, Sin3a, or Mbd3 were normalized for expression of Ube2l3. The graphs show mean relative expression values ± SEM relative to the vector control from two independent series of experiments performed in duplicates. Asterisks indicate significant changes (p < 0.05) derived from Mann-Whitney Rank Sum t-tests. (B) The same RT-qPCR approach was used to determine the effects of 16 further knockdowns of nuclear cofactors on basal and IL-1-inducible Cxcl2 levels as described in detail in the legend of Figure S5 in Supplementary Material. The line graphs show the ranked mean fold changes of normalized Cxcl2 mRNA expression separately analyzed for basal and IL-1-induced conditions. Additionally, the effects on IL-1-mediated regulation (as defined in Figure S3 in Supplementary Material) are depicted. (C) Summarizing venn diagrams indicating the overlapping effects on Cxcl2 mRNA expression of shRNAs directed against 22 nuclear cofactors as identified by shRNA screens I and II. Asterisks indicate the 16 factors that were chosen for validation. (D) Overlap of functions of the shRNAs as found by conventional RT-qPCR. (A–D) Red or blue colors indicate at least 1.5-fold differences between shRNA versus empty vector transfections.
Figure 4Gene-specific requirements of the 16 nuclear cofactors for 6 additional chemokine genes. (A) The same RNA preparations as described in Figure 3B were analyzed for the expression of six further chemokine genes. Shown are ranked fold changes for each mRNA. (B) Heatmaps visualizing the effects of individual knockdowns of cofactors across all genes. Data are ranked by the fold change of basal Cxcl2 mRNA expression. Bar graphs representing all relative expression values are shown in Figure S6 in Supplementary Material. Red or blue colors indicate at least 1.5-fold differences between shRNA versus empty vector transfections.
Figure 5Gene-specific requirements of the 16 nuclear cofactors for 4 additional IL-1 target genes. (A) The same RNA preparations as described in Figure 3B were analyzed for the expression of four additional IL-1 targets representing adhesion molecules (Icam1), cytokines (Il6), and signaling regulators (Nfkbiz, Nfkbia). Shown are ranked fold changes for each mRNA. (B) Heatmaps visualizing the effects of individual knockdowns of cofactors across all genes. Data are ranked by the fold change of basal Cxcl2 mRNA expression as in Figure 4B. Bar graphs representing all relative expression values are shown in Figure S7 in Supplementary Material. Red or blue colors indicate at least 1.5-fold differences between small-hairpin (sh)RNA versus empty vector transfections.
Figure 7A differential set of closely interacting cofactors is required for basal or IL-1-inducible expression of Cxcl2. (A) The entire list of 22 nuclear cofactors as revealed by the combined analysis of both screens was analyzed for known protein:protein interactions of mus musculus using the STRING database (30) with the settings text mining, experiments, databases and coexpression, and a medium confidence score of 0.4. The resulting network was imported into Cytoscape and edges were visualized based on the experimental evidence for protein:protein interactions (edge width) and the STRING combined score (edge color). STRING network analysis also reveals that, compared to the whole genome, the nodes in the network show significantly more interactions than expected. (B) Summarizing scheme of the findings of this study which suggest that downstream of the canonical NF-κB signaling pathway each IL-1-response gene has its own nuclear cofactor requirement. Circles in red (corepressors) or blue (coactivators) colors show the three factors whose knockdowns most strongly activated or suppressed the basal or IL-1-inducible expression of eleven genes. Gray colors mark conditions in which knockdowns failed to deregulate mRNAs by more than 1.5 fold.
Known functions and putative involvement of the 22 cofactors in IL-1, TNF, or NF-κB regulation.
| Nuclear Cofactor (gene symbol) | Alias | Prinicipal function | Implication in IL-1 signaling | Implication in TNF signaling | Implication in NF-κB transactivation | Species, cell types | Reference | |
|---|---|---|---|---|---|---|---|---|
| 1 | BHLHE8, KAT13D | Heterodimeric TF factor (together with BMAL1), regulates circadian expression of genes | IL-1 suppresses Clock-dependent genes | TNF suppresses Clock-dependent genes; Clock enhances TNF-mediated transcription | Binds to p65, enhances NF-κB activity together with BMAL1 | Mouse, human; fibroblasts, epithelial cells | ( | |
| 2 | ZIPK, DLK | Serine/threonine kinase involved in apoptosis, autophagy, transcription, IFNγ expression, granulocyte migration | Knockdown inhibits TNF-induced expression of VCAM-1 | Rat; vascular smooth muscle cells (VSMC) | ( | |||
| 3 | Epl1 | Enhancer of polycomb homolog 1, component of the NuA4 histone acetyltransferase (HAT) complex | ( | |||||
| 4 | H2AZ | Histone variant at promoters/TSS of active and poised genes | ( | |||||
| 5 | JHDM1B, FBXL10, JEMMA | H3K4 and H3K36 demethylase, component of polycomb repressive complexes | ( | |||||
| 6 | JARID1A, RBBP2 | H3K4 demethylase, enhances gene activation by CLOCK:BMAL1, required for IFNγ production of NK cells | Binds to p50 NF-κB | Mouse; splenocytes, NK cells | ( | |||
| 7 | UTX, KABUK2 | H3K27 demethylase, establishes active enhancers, involved in (auto)immune syndromes and T-cell activation | ( | |||||
| 8 | Binds (un)methylated CpG-rich active promoters and enhancers, component of the NuRD complex, essential for mouse development | ( | ||||||
| 9 | MTA1L1, | component of NURD and remodeling complexes, binds to GATA3 in TH2 cells, suppresses IL-2, IL-4, IFNγ expression and autoimmunity | ( | |||||
| 10 | BLHLE74, SRC1 | Transcription coactivator of nuclear receptors | TNF-induced recruitment to IκBα promoter | Ectopically expressed protein enhances p65 transactivation and | Rat, hamster; VSMC | ( | ||
| 11 | RAP250, AIB3, ASC-2, TRBP | Transcription coactivator of nuclear receptors | Binds | Mouse, human, yeast; fibroblasts, epithelial cells | ( | |||
| 12 | PADI-H | Protein-arginine deiminase, catalyzes the citrullination/deimination of histones/other proteins | Protein induced by TNF | No direct evidence | Mouse; VSMC | ( | ||
| 13 | BHC80a | Interacts with and inhibits LSD1 demethylase activity, binds unmethylated H3K4 and COREST | ( | |||||
| 14 | HRMT1L6 | Protein arginine methyltransferase, mediates H3R2, H3R42, H4R3, H2AR3 methylation | Enhances TNF-mediated expression of | Ectopic expression induces | Mouse; tissues and Mefs | ( | ||
| 15 | RSKB, MSK2, p90 RSK | Nuclear protein kinase downstream of ERK and p38 MAPK, phosphorylates H3S10, CREB1, ATF1, suppressor of inflammation | Increased levels of IL-1 in MSK1/2 ko mice in inflammed skin | Suppression of LPS-induced TNF secretion (together with MSK1) | Promotes phosphorylation of p65 at S276 and p65 transactivation, MSK1/2 ko increases skin inflammation | Mouse, human; macrophages, skin, epithelial cells, breast adenocarcinoma | ( | |
| 16 | TIP49A, TAP54-Alpha, INO80H | Chromatin remodeler and ATPase involved in nucleosome sliding | ( | |||||
| 17 | Nuclear scaffold, transcriptional repressor, interacts with HDAC1/2 and multiple other proteins | Upregulation of | Binds to NF-κB subunits during the cell cycle | Human; U2OS sarcoma cells, genetically modified Myr-PIK3 transformed ovarian cancer cells | ( | |||
| 18 | Nuclear scaffold, transcriptional repressor, interacts with MYC and HDAC1/2, binds H3K4me3/H3K36me3-enriched nucleosomes | ( | ||||||
| 19 | SIR2L3 | NAD-dependent class III (histone) deacetylase | Indirect through resveratol-mediated suppression of p65 translocation | Rat; cardiomyocytes | ( | |||
| 20 | KMT5B | methylates H4K20 | ( | |||||
| 21 | TAFII250, NSCL2, CCG1 | Component of TFIID, primary mediator of downstream promoter binding of the preinitiation complex | ( | |||||
| 22 | EPVE6AP, HPVE6A, E6AP | Ubiquitin E3 ligase, interacts with polycomb protein Ring1B, linked to the Angelman syndrome | ( | |||||
.